ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Carbon Monoxide Nanomodulator Reverses Ischemia-Reperfusion Injury in Stroke: A Novel Dual-Channel Therapy Mode of Co-driving Neuroprotection and Neurogenesis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Harmonizing Rigidity and Flexibility: Embedding COF Quantum Dots Into Extracellular Matrix Gel as Carbon Monoxide Depot for Acoustically Triggered Time-Programmable Anti-Infective Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Carbon Monoxide Nanomodulator Reverses Ischemia-Reperfusion Injury in Stroke: A Novel Dual-Channel Therapy Mode of Co-driving Neuroprotection and Neurogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Tailoring Polydopamine Nanoparticle Size Through Synthesis Conditions and Defining Their Antioxidant and Neuroprotective Efficacy.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Recanalization intervention has improved patient outcomes in ischemic stroke, but severe ischemia-reperfusion injury remains a major challenge, necessitating effective pharmacotherapy to reverse neuronal damage and recover neurofunctions. Traditional neuroprotection strategies aim to inhibit neuronal death, and are still insufficient to recover long-term neurological dysfunctions. In this work, it is found that carbon monoxide (CO) as a neuromodulator exerts a new role in promoting neurogenesis via the crosstalk between brain endothelial cells and neural stem cells, which is beyond its recognized roles in anti-inflammation and anti-oxidation. This reveals a new possibility to address the above challenge. Furthermore, this work develops a biomimetic and reactive oxygen species-activated CO nanogenerator to effectively penetrate blood-brain barrier, arrive in stroke-affected regions, and release CO in a controlled manner for an innovative dual-channel therapy strategy via co-driving neuroprotection and neurogenesis. This strategy further demonstrates its therapeutic effects on reversing brain injury and recovering neurofunctions in a mouse ischemic stroke model. This work reveals an important new role of CO, and further offers an advanced pharmacotherapy for long-term neurological dysfunctions in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.